碳纤维汞膜微电极1.5次微分伏安法测定米托蒽醌的研究

米托蒽醌（ＭＸＴ）能吸附在碳纤维汞膜微电极表面，阴极溶出时，产生一个灵敏的１．５次微分溶出峰，其峰电流和米托葱酿的浓度在１．０×１０－５ｍｏｌ／Ｌ～１．３×１０－９ｍｏｌ／Ｌ范围内具有良好的线性关系，经３ｍｉｎ的富集，检出限可达１．０×１０－１０ｍｏｌ／Ｌ，据此建立了测定ＭＸＴ的灵敏的新方法，本文讨论了实验条件，并对血样中的ＭＸＴ进行了测定。     

In vitro investigation of the behaviour of magnetic particles by a circulating artery model

Magnetic drug targeting is the use of coated magnetic nanoparticles as carriers for cytostatic drugs. After intraarterial application of these carriers, they are attracted with an external magnetic field to, for example, an experimental VX2 tumour. The biological compatibility of this system depends on several physiological and physical parameters. We established an in vitro model to simulate in vivo conditions in a circulating system consisting of a circuit with an intact bovine femoral artery close to an external magnetic field. Nanoparticle suspensions were applied by a side inlet. After the magnetisation procedure particle size, concentration and distribution was examined.     

米托蒽醌分子印迹聚邻氨基酚敏感膜传感器的研制

在弱酸性条件下,在金电极上以邻氨基酚为单体和交联剂,米托蒽醌为模板分子,用循环伏安法电聚合成米托蒽醌分子印迹聚邻氨基酚敏感膜传感器。该传感器对米托蒽醌具有良好的选择性和敏感度,米托蒽醌浓度分别在2.0×10^-7—1.0×10^-5mol／L及1.0×10^-5—5.0×10^-5mol／L范围内与峰电流减小量呈线性关系,检出限为1.2×10^-7mol／L。本文同时对分子印迹膜的结构和性能进行了探讨与研究。     

用钼酸盐高灵敏共振瑞利散射法测定米托蒽醌

在盐酸和硝酸介质中用共振瑞利散射法测定了血清和尿液中的米托蒽醌, 结果表明, 该方法的灵敏度高, 对米托蒽醌的检出限为6 ng/mL(硝酸介质)和8 ng/mL(盐酸介质), 可用于血清和尿样中米托蒽醌的测定.     

Surface modification of Mitoxantrone-loaded PLGA nanospheres with chitosan

The purpose of this research was to develop polylactic-co-glycolic acid (PLGA) nanospheres surface modified with chitosan (CS). Mitoxantrone- (MTO-) loaded PLGA nanospheres were prepared by a solvent evaporation technique. The PLGA nanospheres surface was modified with CS by two strategies (adsorption and covalent binding). PLGA nanospheres of 248.4 ± 21.0 nm in diameter characterized by the laser light scattering technique, scanning electron microscopy (SEM) are spherical and its drug encapsulation efficiency is 84.1 ± 3.4%. Zeta potential of unmodified nanospheres was measured to be negative −21.21 ± 2.13 mV. The positive zeta potential of modified nanospheres reveals the presence of CS on the surface of the modified nanospheres. Modified nanospheres were characterized for surface chemistry by X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared (FT-IR). FT-IR spectra exhibited peaks at 3420 cm⁻¹ and 1570 cm⁻¹, XPS spectra shows the N 1s (atomic orbital 1s of nitrogen) region of the surface of the nanospheres, corresponding to the primary amide of CS. In vitro drug release demonstrated that CS-modified nanospheres have many advantages such as prolonged drug release property and decreased the burst release over the unmodified nanospheres, and the modified nanospheres by covalent binding method could achieve the release kinetics of a relatively constant release. These data demonstrate high potential of CS-modified PLGA nanospheres for the anticancer drug carrier.     

Mitochondrion targeting peptide-modified magnetic graphene oxide delivering mitoxantrone for impairment of tumor mitochondrial functions

In this study, we prepared mitochondrion targeting peptide-grafted magnetic graphene oxide (GO) nanocarriers for efficient impairment of the tumor mitochondria. The two-dimensional GOMNP-MitP nanosheets were synthesized by grafting magnetic γ-Fe₂O₃ to the surface of GO, followed by covalent modification of mitochondrion targeting peptide (MitP). GOMNP-MitP exhibited the high capacity of loading the anticancer drug mitoxantrone (MTX), and preferentially targeted the tumor mitochondria. With the aid of alternating magnetic field (AMF), the MTX-loading GOMNP-MitP released MTX to the mitochondria, severely impairing mitochondrial functions, including attenuation of ATP production, decrease in mitochondrial membrane potential (MMP), and further leading to activation of apoptosis. This study realized high-efficient mitochondrion-targeting drug delivery for anticancer therapy by two-dimensional nanoplatforms.     

米托蒽醌与生物大分子DNA结合平衡的研究

米托蒽醌(MX)是一个广谱高效的葸醌类抗癌新药(下式),核酸是该类药物的主要细胞作用靶位,它通过与DNA结合,影响DNA的转译和复制,从而起到抗癌作用。研究这类药物与核酸的作用对于阐明抗癌机理具有重要意义,为此,广泛地开展了这方面的研究。     

米托蒽醌分子印迹传感器的研究及其应用

在弱酸性条件下, 以邻氨基酚为单体交联剂, 米托蒽醌为模板分子, 用循环伏安法电聚合成米托蒽醌分子印迹聚邻氨基酚敏感膜传感器. 该传感器对米托蒽醌具有良好的选择性和敏感度, 米托蒽醌浓度分别在3.3×10-7~1.0×10-5 mol/L及1.0×10-5~5.0×10-5 mol/L范围内与峰电流减小量呈线性关系, 检测下限为1.6×10-7 mol/L, 同时对分子印迹膜的结构和性能进行了研究.     

米托蒽醌在离子注入修饰电极上的伏安行为及其应用

在0.1mol/LNH₃-NH₄Cl缓冲溶液(pH_9.5)中,米托蒽醌在镍离子注入修饰电极上有一灵敏的伏安还原峰,峰电位为-0.85V(vs.SCE).峰电流与米托蒽醌的浓度成线性关系.检出限为1.8×10^-8mol/L.研究了其伏安行为,并将该波用于尿样的测定.结果表明,还原过程为具有吸附性和催化性的准可逆过程.AES和XPS实验表明,Ni已注入到玻碳电极的表面,使电催化活性提高.